Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS

被引：0
|
作者：
Kennedy, GA
Butler, J
Durrant, S
Hill, GR
Western, R
Morton, J
机构：
[1] Royal Brisbane & Womens Hosp, Div Oncol, Brisbane, Qld, Australia
[2] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5410
引用
收藏
页码：438B / 439B
页数：2
相关论文
共 50 条
  • [41] Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma
    McKiernan, Phyllis
    Siegel, David S.
    Vesole, David H.
    Andrews, Tracy
    Biran, Noa
    Rowley, Scott D.
    Skarbnik, Alan P.
    Pecora, Andrew L.
    Callahan, Jacquelyn
    Ortega, Andrea
    Vendivil, Mariefel
    Kaur, Supreet
    McKenna, Marshall
    Donato, Michele L.
    BLOOD, 2018, 132
  • [42] Allogeneic stem cell transplantation (SCT) in children with myelodysplastic syndrome (MDS):: Results of myeloablative therapy with busulfan, cyclophosphamide and melphalan
    Locatelli, F
    Hoogerbrugge, P
    Peters, C
    Bender-Götze, C
    Giraldi, E
    Cecca, M
    Dini, G
    Klingebiel, T
    Zintl, F
    Nürnberger, W
    Messina, C
    Kremens, B
    Pession, A
    Stary, J
    van Wering, E
    Mann, G
    Rogge, T
    Fischer, A
    Zimmermann, M
    Niemeyer, C
    BONE MARROW TRANSPLANTATION, 1999, 23 : S152 - S152
  • [43] Allogeneic stem cell transplantation in AML and MDS - Reduced conditioning for increased risk? The Munich/AMLCG approach
    Schmid, C.
    Schleuning, M.
    Kolb, H. -J.
    ANNALS OF HEMATOLOGY, 2006, 85 : 101 - 104
  • [44] Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
    Kekre, Natasha
    Marquez-Malaver, Francisco J.
    Cabrero, Monica
    Pinana, Jl
    Esquirol, Albert
    Soiffer, Robert J.
    Caballero, Dolores
    Terol, M. J.
    Martino, Rodrigo
    Antin, Joseph H.
    Lopez-Corral, L.
    Solano, Carlos
    Armand, Philippe
    Perez-Simon, Jose A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1808 - 1815
  • [45] A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
    Andersson, Borje S.
    Thall, Peter
    Valdez, Benigno C.
    Ma, Junsheng
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin M.
    Bashir, Qaiser
    Ciurea, Stefan O.
    Gulbis, Alison
    Hosing, Chitra
    Jones, Roy B.
    Kawedia, Jitesh
    Kebriaei, Partow
    Kornblau, Steven M.
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth J.
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BLOOD, 2020, 136
  • [46] Total Marrow Lymphoid Irradiation/Fludarabine/Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation
    Jensen, Lindsay G.
    Stiller, Tracey
    Wong, Jeffrey Y. C.
    Palmer, Joycelynne
    Stein, Anthony
    Rosenthal, Joseph
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (02) : 301 - 307
  • [47] Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning
    DeCook, L. J.
    Thoma, M.
    Huneke, T.
    Johnson, N. D.
    Wiegand, R. A.
    Patnaik, M. M.
    Litzow, M. R.
    Hogan, W. J.
    Porrata, L. F.
    Holtan, S. G.
    BONE MARROW TRANSPLANTATION, 2013, 48 (05) : 708 - 714
  • [48] Clofarabine ± fludarabine with IV busulfan as reduced-toxicity conditioning therapy for allogeneic stem cell transplantation (Allo-SCT) in advanced myeloid leukaemia/MDS
    Andersson, B.
    de Lima, M.
    Worth, L.
    Thall, P.
    Popat, U.
    Jones, R.
    Shpall, E.
    Hosing, C.
    Madden, T.
    Kazerooni, R.
    McAdams, P.
    Alousi, A.
    Kebriaei, P.
    Champlin, R.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S88 - S88
  • [49] COMPARISON OF SUBCUTANEOUS VERSUS INTRAVENOUS ALEMTUZUMAB WITH FLUDARABINE/MELPHALAN BASED CONDITIONING IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
    Plavsa, Alexandra
    Suresh, Tara
    Dalal, Stuti
    Shenoy, Shalini
    Ngwube, Alexander
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 567 - 568
  • [50] Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning
    L J DeCook
    M Thoma
    T Huneke
    N D Johnson
    R A Wiegand
    M M Patnaik
    M R Litzow
    W J Hogan
    L F Porrata
    S G Holtan
    Bone Marrow Transplantation, 2013, 48 : 708 - 714
12345